47例晚期非霍奇金淋巴瘤临床分析及治疗策略的探讨  

THE DISCUSSION OF CLINICAL ANALYSIS AND THERAPUTIC TACTICS OF 47 PATIENTS WITH LATE PHASE NON-HODGKIN'S LYMPHOMA

作　　者：赵耀中[1] 邹德慧[1] 李睿[1] 王亚非[1] 万长春[1] 王国蓉[1] 麦玉洁[1] 李桥川[1] 李云涛[1] 靳风艳[1] 徐燕[1] 林华[1] 钱林生[1] 邱录贵[1] 

机构地区：[1]中国医学科学院中国协和医科大学血液学研究所血液病医院血液5科,天津300020

出　　处：《白血病．淋巴瘤》2004年第4期195-197,共3页Journal of Leukemia & Lymphoma

摘　　要：目的:探讨晚期非霍奇金淋巴瘤(NHL)的临床特点和治疗策略。方法:对47例晚期NHL的临床资料和治疗进行分析。结果:47例晚期NHL的临床特点:骨髓以活跃和明显活跃为主,瘤细胞浸润骨髓占72.2 %,淋巴瘤细胞白血病占34.0 %。细胞遗传学异常占43.9 %,常见超二倍体或少二倍体。CHOP方案有效率为32 %。而BCHOP、BECHOP、MBACOD和ProMACE蛳CytoBOM有效率为54.5 %。BECHOP或MBACOD加美罗华完全缓解率83.3 %。结论:晚期NHL易浸润骨髓,应及时行骨髓检查。采用更为强烈的诱导治疗和增加单克隆抗体治疗药物可取得更为有效的结果。Objective: To discuss clinical characteristics and therapeutic tactics with late phase Non-Hodgkin's lymphoma (NHL). Methods: The clinical data and therapeutic results of 47 patients with late phase NHL were analysed and reviewed. Results: The clinical characteristics with late phase NHL: active proliferation and obvious proliferation is major in bone marrow with late phase NHL patients. Patients of 72.2 % and 34.0 % respectively occurrence infiltration of lymphoma cell and lymphoma cell leukemia in bone marrow. Patients of 43.9 % have abnormal karyotype, especially, hyperdiploid and hypodiploid. The effective rate of being adopted CHOP protocol is 32 %. The effective rate is 54.5 % for taking BCHOP, BECHOP, MBACOD and ProMACE-CytoBOM protocols. However, The complete remission rate is 83.3 % for taking BECHOP or MBACOD+Ritoximab protocols. Conclusion: Because of easily infiltration of bone marrow with late phase NHL patients, we should promptly carry on examination of bone marrow. Induction protocols with the more intense and adding therapeutic medicines of monoclonal antibody may make the more effective results.

关 键 词：临床分析 治疗策略 非霍奇金淋巴瘤 晚期 

分 类 号：R733.1[医药卫生—肿瘤]